GlassScriptPhysician profile
John C Wodynski
NPI 1689943649
$507.04
in general payments reported to CMS, 2019-2025
13 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.99 · 2022: $111 · 2023: $63.58 · 2024: $115 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $87.20 | 2021-2023 | Gattex |
| Kerecis Limited | $77.59 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Novo Nordisk INC | $73.64 | 2025 | Wegovy |
| Medtronic, INC. | $46.41 | 2022-2024 | Ligasure |
| Davol INC. | $44.60 | 2025 | Arista |
| Lilly USA, LLC | $33.82 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Ethicon US, LLC | $33.45 | 2025 | Echelon; Endopath |
| Tactile Systems Technology INC | $25.75 | 2023 | Flexitouch Plus, Entre Plus |
| Teleflex LLC | $20.11 | 2024 | Deknatel |
| E.R. Squibb & Sons, L.L.C. | $18.11 | 2024 | Camzyos |
| Tela Bio, INC. | $17.03 | 2022 | |
| Convatec INC. | $14.89 | 2022 | |
| Kci USA, INC. | $14.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wodynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.